Recombinant Human Syndecan-1 (SDC1), partial (Active)

1. The research revealed identical overall epithelial Sdc1 expression in both breast carcinomas with no statistically significant difference in its stromal expression and confirmed the role of Sdc1 in the progression of both tumor types and in the development of ductal carcinoma's metastatic potential. PMID: 30151336
2. Study demonstrated that miR494 is able to downregulate SDC1 expression, thereby inhibiting the progression of pancreatic cancer. PMID: 29956739
3. High serum SDC1 expression is associated with chemotherapy-resistance in castration-resistant prostate cancer. PMID: 29628317
4. E-Cadherin and epithelial syndecan-1 were more highly expressed in intraluminal/luminal unicystic ameloblastoma than in mural unicystic ameloblastoma and solid/multicystic ameloblastoma, whereas the stromal expression of syndecan-1 was higher in mural unicystic ameloblastoma and solid/multicystic ameloblastoma. PMID: 29850393
5. evamisole inhibited CD138 expression and affected the levels of IL-6 in a dose-dependent manner. The results of the present study add new dimension to levamisole's mode of action as inhibitor of CD138 and IL-6 and as an antiapoptotic agent. PMID: 29798960
6. serum level higher in control group than in early-onset or late-onset pre-eclampsia PMID: 28574293
7. syndecan-1 levels were associated with not only the severity of illness and mortality but also disseminated intravascular coagulation development in sepsis, suggesting that syndecan-1 could be a predictive marker of disseminated intravascular coagulation PMID: 28843664
8. our findings revealed that SDC1 suppressed EMT via the modulation of the ERK signaling pathway that, in turn, negatively affected the invasiveness of human oral cancer cells. Our results provided useful evidence about the potential use of SDC1 as a molecular target for therapeutic interventions in human oral cancer. PMID: 29484435
9. The positive correlation between soluble Syndecan-1 levels and breast cancer tumor size in the present study highlights the importance of this molecule in the breast tumor progression and their significance as tumor biomarkers. PMID: 28382590
10. our results identify the CD63-syntenin-1-ALIX complex as a key regulatory component in post-endocytic HPV trafficking. PMID: 27578500
11. abrogation of nuclear translocation of syndecan-1 resulted in a set of changes clustering in distinct patterns, which highlighted the functional importance of nuclear syndecan-1 in hampering cell proliferation and the cell cycle PMID: 29216821
12. findings support a key role for Sdc1 in modulating pulmonary protection by FFP after hemorrhagic shock. PMID: 28107214
13. S1P induces advanced tumor phenotypes of hepatocellular carcinoma via establishing an MMP-7/syndecan-1/TGF-beta1 autocrine loop PMID: 27556509
14. There was a close correlation between the expression of IL-17 and syndecan-1 in nasal mucosa epithelial cells, glandular epithelial cells, and inflammatory cells, suggesting that IL-17 and syndecan-1 may play a role, and interact with each other, in the pathogenesis of non- eosinophilic chronic rhinosinusitis with nasal polyps. PMID: 28585128
15. the present study showed that serum Syndecan-1 might be a reliable marker for monitoring disease activity and renal activity in children with JSLE and lupus nephritis. PMID: 27838471
16. The above suggest that radiation-mediated premature senescence and invasive tumor cells, alone or in combination, enhance SDC1 expression in breast stromal fibroblasts, a poor prognostic factor for cancer growth, and that TGF-beta plays a crucial role in this process. PMID: 27434331
17. A syndecan-1 level >/=40 ng/mL identified trauma patients with significantly worse outcomes, despite admission physiology similar to those without the condition. PMID: 28579548
18. MiR-331-3p-mediated miRNA maturation and enhanced epithelial-to-mesenchymal transition via effects on TGF-beta/Smad 4 and Dicer are essential for the development of prostate cancer mediated by syndecan-1. PMID: 26259043
19. The heparanase/syndecan1 axis in gallbladder carcinoma cells plays an important role in the invasion and metastasis, thus providing a new therapeutic target. PMID: 28351285
20. Syndecan-1 acts as a novel tissue biomarker and a modulator of CSC phenotype of triple negative IBC via the IL-6/STAT3, Notch and EGFR signaling pathways, thus emerging as a promising therapeutic target for IBC. PMID: 28270211
21. Hepatitis C virus infection downregulates Synd-1 and upregulates Xylt 2 expression, likely contributing to a major glycocalyx reshuffle within days of infection. PMID: 27930836
22. Soluble Sdc1 is significantly lower before the clinical onset of preeclampsia, with reduced expression of Sdc1 in the delivered placenta, suggesting a role for glycocalyx disturbance in preeclampsia pathophysiology. PMID: 27299886
23. Heparanase has emerged as a major regulator of cancer by degrading heparan sulfate thereby influencing multiple signaling pathways that control gene expression, syndecan shedding and cell behavior. (Review) PMID: 27758044
24. Study provides robust evidence in favor of the additional baseline soluble CD138 prognostic value for OS, in mCRC patients. A simple biological scoring system is proposed including LDH and CD138 binary status values. PMID: 27472156
25. it is not appropriate to assume that CD138 expression in urothelial carcinomas is specific for plasmacytoid variants PMID: 27305940
26. epithelial cytoplasmic expression of maspin and CD138 may have a significant role in tumorigenesis in ovarian high-grade serous carcinomas and clear cell carcinomas; these markers may regulate tumor cell proliferation, and their significant correlation to each other may suggest that CD138 probably induces maspin expression to protect tumor growth factors from being lysed by proteolytic enzymes PMID: 26526579
27. High syndecan level is associated with sepsis. PMID: 26953518
28. Systemic sclerosis (SSc) patients with elevated serum syndecan-1 levels had higher prevalence of telangiectasia, elevated right ventricular systolic pressure and decreased diffuse capacity of the lung for carbon monoxide than those with normal levels. Therefore, soluble syndecan-1 may be related to the development of proliferative vasculopathy in SSc patients. PMID: 26076711
29. in colorectal adenomas, the heparanase-1 does not participate in syndecan-1 degradation; the heparanase-2 does not stimulate syndecan-1 degradation by the action of heparanase-1, and the heparanase-2 may be involved in the modulation of the heparanase-1 activity. PMID: 26972718
30. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts. PMID: 26460958
31. The new markers were able to identify a clonal CD138-negative population as minimal residual disease in the bone marrow and peripheral blood of MM patients. PMID: 26729247
32. miR-145 suppresses syndecan-1 and, by this mechanism, up-regulates stem cell factors and induces cell senescence and differentiation. PMID: 26514209
33. The results suggest that Sdc1 may modulate fibronectin fibrillogenesis and/or alter cell morphology during ECM production through alphavbeta3 integrin, thereby mediating ECM fiber alignment. PMID: 26909794
34. Syndecan-1 on epithelial tumor cells promotes MIF binding and MIF-mediated cell migration. This may represent a relevant mechanism through which MIF enhances tumor cell motility and metastasis. PMID: 26852939
35. SULF1 levels are lower in pleural malignancies compared to benign conditions and inversely correlate with the amounts of syndecan-1, suggesting important roles for syndecan-1 and SULF1 in malignant mesothelioma. PMID: 26210886
36. Our study indicates that SDC1 expressed by the bone marrow microenvironment is involved in angiogenesis in MM. PMID: 25353275
37. miR-302a plays a key role in inhibition of ovarian cancer cell proliferation, and enhancing apoptosis by targeting SDC1. PMID: 26191180
38. The concentration of syndecan-1, a marker of glycocalyx damage measured during ED admission, is valuable in assessing the risk of developing AKI and in-hospital mortality. PMID: 25891890
39. Sdc-1 may act as a modulator of ESC apoptosis and probably invasion depth as a crucial factor for successful pregnancy. PMID: 25830352
40. Elevated levels of soluble CD138/Sdc-1 in older bladder cancer patients and those with muscular invasion sheds some light on the mechanisms of the disease invasion. PMID: 25115297
41. demonstrate that HER2 is captured via a site, comprised of amino acids 210-240, in the extracellular domain of human Sdc1, and EGFR is captured via an extracellular site comprised of amino acids 87-131 in human Sdc4 PMID: 26350464
42. stromal changes in the expression of SDC-1 may originate from the stroma and contribute to the pathogenesis and metastatic potential of epithelial ovarian carcinoma PMID: 26513873
43. syndecan-1 has a role in glycocalyx shedding and is increased in patients with end-stage liver disease; ischemia-reperfusion injury during OLT further exacerbates glycocalyx shedding PMID: 25757215
44. Data indicate that the extracellular and cytoplasmic domains of syndecans 1/2/3/4 are intrinsically disordered regions. PMID: 24956062
45. HPV16 particles binds to heparan sulfate and syndecan-1 molecules present in the extracellular matrix. PMID: 26289843
46. syndecan-1 may have a role as a biological and prognostic marker in patients with triple-positive breast carcinomas PMID: 25273930
47. our findings identify heparanase as a modulator of the syndecan-syntenin-ALIX pathway, fostering endosomal membrane budding and the biogenesis of exosomes by trimming the heparan sulfate chains on syndecans PMID: 25732677
48. Serum SDC-1 levels are increased in systemic lupus erythematosus patients with nephritis, indicating that SDC-1 might be a useful serum biomarker for active LN. PMID: 25512478
49. Syndecan-1 expression is associated with tumor size and EGFR expression in colorectal carcinoma PMID: 25589885
50. syndecan-1 in pleural effusions predicted a survival difference for patients with pleural metastatic disease and malignant mesothelioma. PMID: 25147801

Show More

Hide All

HGNC: 10658

OMIM: 186355

KEGG: hsa:6382

STRING: 9606.ENSP00000254351

UniGene: Hs.224607